Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 8Gastrointestinal 4Thoracic 3Gynecologic 3Breast 3Genitourinary 2CNS 1

Conditions

Breast Neoplasms 22Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Neoplasm Metastasis 6Pancreatic Neoplasms 5Ovarian Neoplasms 5Colorectal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Melanoma 3Colonic Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Thrombocytosis 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

pembrolizumab 33Docetaxel 10Nivolumab 9Paclitaxel 6Trastuzumab 5Gemcitabine 5Cetuximab 5Carboplatin 5Capecitabine 5Fulvestrant 4Cyclophosphamide 4spartalizumab 3poly ICLC 3durvalumab 3avelumab 3Oxaliplatin 3Leucovorin 3Ipilimumab 3Fluorouracil 3Cisplatin 3Biopsy 3zimberelimab 2tremelimumab 2palbociclib 2obinutuzumab 2lenvatinib 2cemiplimab 2budigalimab 2Vorinostat 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × Oxaliplatin × Breast × Clear all
NCT05891171 2026-03-31

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

AstraZeneca

Phase 1 Completed
32 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡